Why Rezolute, Inc.’s (RZLT) Stock Is Down 5.52%
As of Friday, August 28, Rezolute, Inc.’s RZLT share price has dipped by 5.52%, which has investors questioning if this is right time to buy.Jenna Brashear
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
COMPANY SUMMARY
Rezolute, Inc., a late-stage rare disease company, focused on improving outcomes for individuals with hypoglycemia caused by hyperinsulinism in the United States. Its lead clinical asset is ersodetug, an intravenously administered human monoclonal antibody that is in Phase 3 clinical trial for the treatment of congenital hyperinsulinism, an ultra-rare pediatric genetic disorder, as well as for the treatment of hypoglycemia; and clinical trials of ersodetug for tumor hyperinsulinism. The company was formerly known as AntriaBio, Inc. and changed its name to Rezolute, Inc. in December 2017. Rezolute, Inc. was founded in 2010 and is headquartered in Redwood City, California.
Commentary & Analysis
Why Rezolute, Inc.’s (RZLT) Stock Is Down 6.29%
As of Monday, August 24, Rezolute, Inc.’s RZLT share price has dipped by 6.29%, which has investors questioning if this is right time to buy.Michael Rose
Why Rezolute, Inc.’s (RZLT) Stock Is Up 8.80%
As of Friday, August 21, Rezolute, Inc.’s RZLT share price has surged by 8.80%, which has investors questioning if this is right time to sell.Jenna Brashear
Why Rezolute, Inc.’s (RZLT) Stock Is Down 5.53%
As of Friday, July 31, Rezolute, Inc.’s RZLT share price has dipped by 5.53%, which has investors questioning if this is right time to buy.Rosalio Madrigal
Why Rezolute, Inc.’s (RZLT) Stock Is Up 8.20%
As of Tuesday, July 21, Rezolute, Inc.’s RZLT share price has surged by 8.20%, which has investors questioning if this is right time to sell.Michael Rose
Financial Summary
| Share Statistics | RZLT | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $478.5 | $282.4 | 36% |
|
| Shares Out (Mil) | 104.0 | 54.0 | 63% |
|
| Institutional Ownership | 99.0% | 93.1% | 84% |
|
| Float (Mil) | 65.6 | 42.2 | 53% |
|
| Beta | 0.67 | 0.94 | 39% |
|
| Avg Daily Volume (000s) | 1,045 | 482 | 73% |
|
| Price Change (52-week) |
(37.9%) | 59.9% | 20% |
|
| Growth | RZLT | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | na | 14.1% | na |
|
| Net Income (5yr) | (29.7%) | (10.1%) | 14% |
|
| EPS (5yr) | 22.6% | 15.9% | 72 |
|
| Dividends (5yr) | na | 0.0% | na |
|
| Cash Flow (5yr) | 25.5% | (15.6%) | 83% |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | 8 | 8 | 8 | |
| Current EPS | ($0.143) | ($0.695) | ($0.626) | |
| Month Ago EPS | ($0.143) | ($0.695) | ($0.626) | |
| # Rev Up | 1 | 0 | 1 | |
| # Rev Down | 0 | 1 | 2 | |
| Three Months Ago EPS | ($0.143) | ($0.695) | ($0.626) | |
| Year/Year Chg | (7.7%) | (29.1%) | (71.4%) | |
| Financials | RZLT | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | na | $37 | na |
|
| Net Income (TTM) (Mil) | ($82) | ($43) | 13% |
|
| EPS (TTM) | ($0.804) | ($1.500) | 23% |
|
| Operating Cash Flow (TTM) (Mil) | ($74) | ($31) | 7% |
|
| Net Cash Flow (TTM) (Mil) | ($3) | $2 | 36% |
|
| Long-Term Debt (Q1) (Mil) | $0 | $4 | 14% |
|
| Enterprise Value (Q1) (Mil) | $229 | $190 | 27% |
|
| Valuation | RZLT | Industry Median |
Percentile (All Stocks) |
|
| P/B | 4.09 | 2.84 | 73% |
|
| P/E | na | 20.2 | na |
|
| Dividend Yield | na | 0.0% | na |
|
| PEG (5yr hist) | na | 1.0 | na |
|
| Ratios | RZLT | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | na | 66.9% | na |
|
| Net Margin | na | (74.2%) | na |
|
| ROA | (74.0%) | (47.7%) | 8% |
|
| ROE | (81.7%) | (55.0%) | 11% |
|
| Liabilities to Assets | 6.9% | 29.8% | 4% |
|
| F-Score | 4 | 3 | 33% |
|
Rezolute, Inc. did not pass any screens on 9/4/2026.
